Enbrel “Black Box” Under Consideration By FDA, Amgen Execs Say
This article was originally published in The Pink Sheet Daily
Executive Summary
Amgen also has received two federal subpoenas related to its products, the firm discloses.
You may also be interested in...
Enbrel Label Gets “Black Box” On Tuberculosis Risk
Package insert for Amgen/Wyeth biologic now more in line with other TNF inhibitors.
Enbrel Label Gets “Black Box” On Tuberculosis Risk
Package insert for Amgen/Wyeth biologic now more in line with other TNF inhibitors.
Enbrel Phase III Data Shows Significant Improvement In Pediatric Psoriasis
Enbrel could be the first biologic to treat pediatric patients' chronic moderate to severe plaque psoriasis.